Valneva SE (VALN) Change in Working Capital (2021 - 2026)
Valneva SE (VALN) posted quarterly Change in Working Capital of $19.6 million for Q1 2026, up 287.73% year-on-year from $5.1 million in Q1 2025, and up 16349.06% on a QoQ basis from -$120623.2 in Q4 2025.
Valneva SE (VALN) Change in Working Capital (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Change in Working Capital for 6 consecutive years, with $19.6 million the latest figure, recorded in Q1 2026.
- Quarterly Change in Working Capital rose 287.73% year-over-year to $19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.7 million (up 112.07% YoY) and the FY2025 annual result came in at $1.7 million, down 87.09% from the prior year.
- Change in Working Capital climbed to $19.6 million in Q1 2026 per VALN's latest filing, from -$120623.2 in the prior quarter.
- Over the last five years, Change in Working Capital for VALN reached as high as $48.6 billion in Q3 2023 and fell as low as -$48.7 billion in Q2 2023.
- A 5-year average of $11.6 million and a median of -$120623.2 in 2025 frame the typical range for Change in Working Capital.
- The largest YoY upside for Change in Working Capital was 38763.39% in 2023 against a maximum downside of 28988.81% in 2023.
- Year by year, Change in Working Capital stood at -$57.5 million in 2022, then soared by 572.51% to $271.9 million in 2023, then tumbled by 80.55% to $52.9 million in 2024, then sank by 100.23% to -$120623.2 in 2025, then soared by 16349.06% to $19.6 million in 2026.
- According to Business Quant data, Change in Working Capital over the past three periods registered $19.6 million, -$120623.2, and $10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 19.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.60 Mn |
| Mar 31, 2026 | 19.60 Mn |
| Dec 31, 2025 | -120,623.15 |
| Dec 31, 2025 | -120,623.15 |
| Sep 30, 2025 | 10.66 Mn |
| Sep 30, 2025 | 10.66 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | -10.44 Mn |
| Mar 31, 2025 | -10.44 Mn |
| Dec 31, 2024 | 52.88 Mn |
| Dec 31, 2024 | 52.88 Mn |
| Sep 30, 2024 | -4.46 Mn |
| Sep 30, 2024 | -4.46 Mn |
| Jun 30, 2024 | -23.02 Mn |
| Jun 30, 2024 | -23.02 Mn |
| Mar 31, 2024 | -12.43 Mn |
| Mar 31, 2024 | -12.43 Mn |
| Dec 31, 2023 | 271.87 Mn |
| Dec 31, 2023 | 271.87 Mn |